Replies to post #308074 on Avid Bioservices Inc (CDMO)

[biopharm]

Stanford ...has Rosemarie and other names of interest on that patent and now just filed a new one with Novartis

Justia Patents Rosemarie H. DeKruyff Inventions, Patents and Patent Applications


Patents by Inventor Rosemarie H. DeKruyff
Rosemarie H. DeKruyff has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

ANTIBODY MOLECULES TO TIM-3 AND USES THEREOF
Publication number: 20170198041
Abstract: Antibody molecules that specifically bind to TIM-3 are disclosed. The anti-TIM-3 antibody molecules can be used to treat, prevent and/or diagnose immune, cancerous, or infectious conditions and/or disorders.
Type: Application
Filed: February 14, 2017
Publication date: July 13, 2017
Inventors: Catherine Anne Sabatos-Peyton, Barbara Brannetti, Alan S. Harris, Thomas Huber, Thomas Pietzonka, Jennifer Marie Mataraza, Walter A. Blattler, Daniel J. Hicklin, Maximiliano Vasquez, Rosemarie H. DeKruyff, Dale T. Umetsu, Gordon James Freeman, Tiancen Hu, John A. Taraszka, Fangmin Xu
ANTIBODY MOLECULES TO TIM-3 AND USES THEREOF
Publication number: 20170190777
Abstract: Antibody molecules that specifically bind to TIM-3 are disclosed. The anti-TIM-3 antibody molecules can be used to treat, prevent and/or diagnose immune, cancerous, or infectious conditions and/or disorders.
Type: Application
Filed: March 17, 2017
Publication date: July 6, 2017
Inventors: Catherine Anne Sabatos-Peyton, Barbara Brannetti, Alan S. Harris, Thomas Huber, Thomas Pietzonka, Jennifer Marie Mataraza, Walter A. Blattler, Daniel J. Hicklin, Maximiliano Vasquez, Rosemarie H. DeKruyff, Dale T. Umetsu, Gordon James Freeman, Tiancen Hu, John A. Taraszka, Fangmin Xu
BLOCKADE OF RGMb FOR REDUCING TRANSPLANTATION-ASSOCIATED IMMUNE RESPONSES
Publication number: 20170121404
Abstract: RGMb antagonists reduce undesirable immune responses associated with tissue or organ transplantation.
Type: Application
Filed: November 3, 2016
Publication date: May 4, 2017
Inventors: Everett Hurteau Meyer, Rosemarie H. Dekruyff, Panagiota Iliopoulou, Yuchiao Hsu, Magdiel Perez Cruz
BLOCKADE OF TIM-1 FOR TREATING GRAFT-VERSUS-HOST DISEASE
Publication number: 20170101471
Abstract: TIM1 antagonists reduce GVHD by symptom score and show statistically significant improved survival.
Type: Application
Filed: October 6, 2016
Publication date: April 13, 2017
Inventors: Panagiota Iliopoulou, Rosemarie H. Dekruyff, Everett Hurteau Meyer
Antibody molecules to TIM-3 and uses thereof
Patent number: 9605070
Abstract: Antibody molecules that specifically bind to TIM-3 are disclosed. The anti-TIM-3 antibody molecules can be used to treat, prevent and/or diagnose immune, cancerous, or infectious conditions and/or disorders.
Type: Grant
Filed: January 30, 2015
Date of Patent: March 28, 2017
Assignees: Novartis AG, DANA-FARBER CANCER INSTITUTE, INC., Children's Medical Center Corporation
Inventors: Catherine Anne Sabatos-Peyton, Barbara Brannetti, Alan S. Harris, Thomas Huber, Thomas Pietzonka, Jennifer Marie Mataraza, Walter A. Blattler, Daniel J. Hicklin, Maximiliano Vasquez, Rosemarie H. DeKruyff, Dale T. Umetsu, Gordon James Freeman, Tiancen Hu, John A. Taraszka, Fangmin Xu

http://patents.justia.com/inventor/rosemarie-h-dekruyff

_______

Interesting how it says "loops of PtdSer..."
http://patents.justia.com/patent/9605070

[biopharm]

PS Targeting patents / LettersToBOD2.0

How many patents mention targeting Phosphatidylserine and how many more are there out there? or en route? a few published online very recently ...

Now to keep this certified letter to BODs moving along, and because there are so many damn puzzle pieces ....we must assume that the BODs likely are not up to speed on the patents out there that that simply cross over to PS Targeting and ask yourself this, when someone says it has no value, why in the hell are others like Bayer and Novartis speaking out about PS Targeting within their MOST RECENTLY filed patents ??

There is astronomical value ....that is why!

One letter is not enough, for me at least.....because I completely forget to ask if the new BODs have been given an expert review/ analysis on these other patents that Bayer Novartis Dana Farber etc have been filing?

I bet they have not ....and to play it safe it may be a good idea to send a 2nd certified letter focused on the PS Targeting IP which is up for sale and/or license and make damn sure all BODs realize they sit on the tip of an iceberg of new, daily new ....PS Targeting blitz of information that Stephen White fails miserably at trying to conclude it has not much value. Is Stephen White working next to Jeanette Bleecker it seems or maybe on the same payroll...

Read this prior post and I will start building off this post with all the Big Pharmas that make mention of Phosphatidylserine targeting and guess where the validation will be .....?

BIOMARKERS